Figure 3.

LAP^Hi myeloid cells dampen tumor-specific immunity in vivo

(A) CT26 CRC tumor volume over time in WT mice treated with either anti-LAP or isotype control (IC) antibodies (n = 11).

(B) Effect of anti-LAP antibody treatment on myeloid cells (CT26 model). Mice were treated with anti-LAP or IC antibodies and frequencies of cells in the spleen measured by flow cytometry.

(C) MC38 CRC tumor volume over time in WT mice treated with either anti-LAP or IC antibodies (n = 5).

(D) Effect of anti-LAP antibody treatment on myeloid cells (MC38 model). Mice were treated with anti-LAP or IC antibodies and frequencies of cells in the spleen measured by flow cytometry.

(E) MC38 tumor volumes over time in WT mice adoptively transferred with LAP^Hi and LAP^Lo MCs (n = 5).

(F) Foxp3⁺ Tregs measured in the spleen of mice transferred with LAP^Lo or LAP^Hi MCs. Representative FACS plots (right panel) and quantification (left panel) are shown (n = 4).

(G) CD103⁺Foxp3⁺ Tregs measured in the spleen of mice adoptively transferred with LAP^Hi or LAP^Lo MCs. Representative FACS plots (right panel) and quantification (left panel) are presented (n = 4).

(H) LAP⁺ CD4 Tregs measured in the spleen of mice adoptively transferred with LAP^Hi or LAP^Lo MCs. Representative FACS plots (right panel) and quantification (left panel) are shown (n = 4). Data shown as mean ± SEM. Two-way ANOVA (A, C, and E) and two-tailed t test (B, D, and F–H) were used for p value calculations. ∗∗∗∗, p < 0.0001. See also Figure S2.